MM-402 is under clinical development by Mind Medicine MindMed and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MM-402’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Midomafetamine (MM-402) is under development for the treatment of social anxiety disorder and autism spectrum disorder. The drug candidate is R (-) enantiomer of 3,4-methylenedioxymethamphetamine (MDMA). It acts by targeting monoamine oxidase (MAO), sodium-dependent dopamine transporter (SLC6A3) and sodium-dependent noradrenaline transporter (SLC6A2).
Mind Medicine MindMed overview
Mind Medicine MindMed (MindMed) is a pharmaceutical drug development and clinical research company. The company develops medicinal products to treat brain health disorders, psychiatry, pain and substance use disorders, and related therapeutic areas. Its product offerings include psychedelic and empathogen drugs. The company offers research and development supports such as non-clinical, pre-clinical, human clinical trials and investigator-initiated trials. It also develops drugs support clinical data opportunity in autism spectrum disorders (ASD), address a critical gap in opioid use disorder (OUD) treatment. MindMed is headquartered in New York, the US.
For a complete picture of MM-402’s drug-specific PTSR and LoA scores, buy the report here.